DOCSLIB.ORG

Manufacturers with Signed Rebate Agreements September 1 , 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manufacturers with Signed Rebate Agreements September 1 , 2010 Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements September 1 , 2010 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 Y 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC. 1/1/1991 Y 00031 LEDERLE PIPERACILLIN 1/1/1991 Y 00206 ELKINS-SINN 1/1/1991 Y 00032 INTERNATIONAL LABORATORIES 1/1/1991 Y 00212 SANDOZ NUTRITION 1/1/1991 00037 CARTER- WALLACE, INC. 1/1/1991 Y 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00039 HOECHST MARION ROUSSEL INC. 1/1/1991 00225 B F ASHER COMPANY INC., 1/1/1991 00045 MCNEIL PHARMACEUTICAL 1/1/1991 Y 00228 PUREPAC PHARM. CO, DIV KALIPHA 1/1/1991 Y 00046 LEDERLE PARENTERALS 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES IN 1/1/1991 Y 00049 PFIZER-ROERIG 1/1/1991 Y 00256 FLEMING AND COMPANY 10/1/1991 Y 00051 UNIMED PHARMACEUTICALS, INC 10/1/1997 Y 00258 INWOOD LABORATORIES INC 1/1/1991 Y 00052 ORGANON INC. 1/1/1991 00259 MERZ PHARMACEUTICALS 1/1/1991 00053 AVENTIS BEHRING 1/1/1991 00264 B BRAUN MEDICAL, INC. 1/1/1991 00054 ROXANE LABORATORIES, INC. 1/1/1991 Y 00276 MISEMER PHARMACEUTICAL, INC. 10/1/2006 00056 DU PONT PHARMACEUTICALS 1/1/1991 Y 00277 LASER INC 1/1/1991 Y 00062 ORTHO MCNEIL PHARMACEUTICAL 1/1/1991 Y 00281 SAVAGE LABS, DIV OF ALTANA INC 1/1/1991 Y 00064 HEALTHPOINT LTD 7/1/1995 Y 00288 FLUORITAB CORPORATION 10/1/1991 00065 ALCON LABORATORIES, INC. 1/1/1991 Y 00299 GALDERMA, L.T. 1/1/1991 00066 DERMIK LABORATORIES 1/1/1991 00300 TAP PHARMACEUTICALS INC 1/1/1991 Y 00067 NOVARTIS CONSUMER HEALTH INC 1/1/1991 00310 ASTRAZENECA LP 1/1/1991 Y 00068 HOECHST MARION ROUSSEL INC. 1/1/1991 00327 UNITED GUARDIAN, INC. 1/1/1991 Y 00069 PFIZER INC 1/1/1991 Y 00338 BAXTER HEALTHCARE CORPORATI 1/1/1991 Y 00071 WARNER-LAMBERT 1/1/1991 Y 00378 MYLAN PHARMACEUTICALS, INC. 1/1/1991 Y 00072 APOTHECON INC 1/1/1991 00406 MALLINCKRODT SPECIALTY CHEMI 7/1/1993 Y 00074 ABBOTT LABORATORIES 1/1/1991 Y 00409 HOSPIRA, INC 1/1/2005 00075 RHONE-POULENC RORER PHARMA 1/1/1991 00414 SUPPOSITORIA LABORATORIES 4/1/1994 Y 00078 NOVARTIS PHARMACEUTICALS 1/1/1991 Y D 00421 THE FIELDING PHARMACEUTICAL C 1/1/1991 9/30/2010 Y 00083 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00430 WARNER CHILCOTT LABORATORIE 1/1/1998 00085 SCHERING PLOUGH PHARMACEUTI 1/1/1991 00456 FOREST PHARMACEUTICALS INC 1/1/1991 Y 00087 BRISTOL-MYERS SQUIBB COMPANY 1/1/1991 Y 00462 PHARMADERM 7/1/2003 00088 HOECHST MARION ROUSSEL, INC. 1/1/1991 00469 LYPHOMED DIVISION FUJISAWA US 1/1/1991 Y 00089 3M PHARMACEUTICALS 1/1/1991 Y 00472 ALPHARMA, USPD 1/1/1991 Y 00091 KREMERS URBAN CO. 1/1/1991 Y 00482 BRADLEY PHARMACEUTICALS, INC. 1/1/1991 Y 00093 TEVA PHARMACEUTICALS 1/1/1991 Y 00485 EDWARDS PHARMACEUTICALS, IN 1/1/1991 Y 00095 ECR PHARMACEUTICALS 7/1/1993 Y 00486 BEACH PRODUCTS INC 1/1/1991 Y 00096 PERSON & COVEY INC. 4/1/1999 00487 NEPHRON PHARMACEUTICALS CO 4/1/1992 Y 00113 L. PERRIGO COMPANY 7/1/2003 00496 FERNDALE LABORATORIES INC. 1/1/1991 Y 00115 GLOBAL PHARMACEUTICAL COMPA 1/1/1991 Y 00517 AMERICAN REGENT LABS, INC. 7/1/1993 00116 XTTRIUM LABORATORIES, INC 1/1/2002 Y 00525 PAN AMERICAN LABORATORIES IN 1/1/1991 Y 00121 PHARMACEUTICAL ASSOCIATES, IN 1/1/1991 Y 00527 LANNETT COMPANY INC. 7/1/1994 Y Page 1 of 6 N = NEW; D = DELETED; X = COVERED (NO REBATE AGREEMENT); Y=SENIORCARE REBATE AGREEMENT ON FILE Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements September 1 , 2010 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00535 GILBERT LABORATORIES 7/1/2002 Y 11399 GTX, INC 7/1/2005 Y 00536 WATSON PHARMA, INC 1/1/1991 Y 11523 SCHERING PLOUGH HEALTHCARE 4/1/2003 00548 INTERNATIONAL MEDICATION SYS 1/1/1991 Y 11528 CENTRIX PHARMACEUTICAL, INC 7/1/2006 Y 00555 BARR LABORATORIES INC 1/1/1991 Y 11530 GLAXOSMITHKLINE 4/1/2002 Y 00573 WYETH AYERST LABORATORIES 1/1/1991 11701 COLOPLAST CORPORATION 10/1/1991 Y 00574 PADDOCK LABORATORIES, INC. 1/1/1991 Y 11980 ALLERGAN INC 1/1/1991 Y 00575 BAKER NORTON PHARMACEUTICAL 1/1/1991 Y 12496 RECKITT & COLMAN PHARMACEUTI 1/1/1994 00590 DU PONT PHARMACEUTICALS 1/1/1991 Y 12593 RED RIIVER PHARMA MANUFACTUR 4/1/2006 00591 WATSON PHARMA, INC 7/1/2001 Y 12830 R.A. MCNEIL 1/1/1991 Y 00597 BOEHRINGER INGELHEIM PHARMA 1/1/1991 Y 12939 MARLOP PHARMACEUTICALS, INC. 1/1/1991 00603 QUALITEST PRODUCTS, INC. 1/1/1991 Y 12948 NITROMED INC 10/1/2005 00615 VANGUARD LABS, INC 1/1/1991 Y 13107 AUROBINDO PHARMA USA, INC 7/1/2005 Y 00641 ESI LEDERLE, INC 1/1/1991 Y 13279 ALLAN PHARMACEUTICALS, LLC 10/1/2005 00642 EVERETT LABORATORIES 1/1/1991 Y 13310 A R SCIENTIFIC, INC 1/1/2006 Y 00677 UNITED RESEARCH LABORATORIE 1/1/1991 Y 13436 VENUS 1/1/2009 00682 MARNEL PHARMACEUTICALS INC 1/1/1991 13453 GRACEWAY PHARMACEUTICALS, L 4/1/2007 Y 00703 GENSIA SICOR PHARMACEUTICALS 7/1/1992 Y 13478 BARRIER THERAPEUTICS 1/1/2006 00713 G AND W LABORATORIES INC 1/1/1991 Y 13533 TALECRIS BIOTHERAPEUTICS, INC 10/1/2005 00777 DISTA PRODS CO DIV OF ELI LILLY 1/1/1991 Y 13548 CORIA LABORATORIES, LTD 4/1/2006 00781 GENEVA PHARMACEUTICALS, INC., 1/1/1991 Y 13551 FSC LABORATORIES, INC 1/1/2006 00785 UAD LABORATORIES INC 1/1/1991 Y 13632 ROSEMONT PHARMACEUTICALS LT 7/1/2007 00813 PHARMICS INC. 1/1/1991 13668 TORRENT PHARM, INC. 10/1/2007 Y 00832 USL PHARMA, INC 1/1/1991 Y 13811 TRIGEN LABORATORIES, INC. 4/1/2006 00884 PEDINOL PHARMACAL INC 1/1/1991 Y 13845 DBA THE CHAO CENTER 4/30/2009 00904 MAJOR PHARMACEUTICALS 1/1/1991 Y 13913 DEPOMED, INC 10/1/2005 00941 BAXTER HEALTHCARE CORP. 4/1/2010 13925 SETON PHARMACEUTICALS, LLC 11/18/2008 00944 BAXTER BIOTECH 1/1/1991 14168 STONEBRIDGE PHARMA , LLC 1/1/2007 Y 00955 SANOFI SYNTHELABO 1/1/1996 14508 SUN PHARMACEUTICAL INDUSTRIE 7/1/2006 Y 00998 ALCON -PUERTO RICO- INC. 1/1/1991 Y 14550 ACTAVIS PHARMA MFGING PRIVAT 4/27/2010 Y 08880 KENDALL HEALTHCARE PRODUCTS 1/1/1991 15054 TERCICA, INC 4/1/2006 08884 SHERWOOD MEDICAL 1/1/1991 15127 SELECT BRAND DISTRIBUTORS 10/1/2006 10019 BAXTER HEALTHCARE CORPORATI 10/1/2001 Y 15210 OTN GENERICS, INC. 10/1/2006 10122 CORNERSTONE BIOPHARM, INC 7/1/2005 15330 GENPHARM, L.P. 4/1/2006 Y 10139 GENERALMEDIX, INC. 12/9/2008 15338 APACE KY, LLC 1/1/2009 Y 10144 ACORDA THERAPEUTICS, INC 10/1/2005 15370 CARWIN ASSOCIATES, INC. 10/1/2006 Y 10147 PATRIOT PHARMACEUTICALS, LLC 4/1/2005 Y 15456 ESPRIT PHARMA, INC. 4/1/2006 Y 10148 COTHERIX, INC 7/1/2005 15584 BRISTOL-MYERS SQUIBB & GILEAD 7/1/2006 Y 10158 GLAXOSMITHKLINE 4/1/2002 Y 15686 MIDLAND HEALTHCARE, LLC 4/1/2006 10267 CONTRACT PHARMACAL CORP 1/1/1991 Y 15821 FOCUS LABORATORIES, INC. 10/1/2006 10337 DOAK DERMATOLOGICS DIV 7/1/2002 Y 16103 PHARBEST PHARMACEUTICALS, IN 10/1/2006 10370 ANCHEN PHARMACEUTICALSINC 7/1/2007 16252 COBALT LABORATORIES, INC 10/1/2006 Y 10454 SOLSTICE NEUROSCIENCES, INC 1/1/2006 16477 LASER PHARMACEUTICALS, LLC 7/1/2006 Y 10542 HILLESTAD INTERNATIONAL, INC. 4/1/1994 Y 16571 PACK PHARMACEUTICALS, L.L.C. 4/1/2006 Y 10572 AFFORDABLE PHARMACEUTICALS, 1/1/2005 Y 16714 NORTHSTAR RX, LLC 4/1/2008 Y 10631 RANBAXY LABORATORIES INCORP 10/1/2005 16729 ACCORD HEALTHCARE INC. 7/1/2008 Y 10702 KVK TECH INC 1/1/2007 Y 16781 ONSET THERAPEUTICS 7/1/2006 10768 PERRIGO PHARMACEUTICALS CO 4/1/2005 16887 VERNALIS PHARMACEUTICALS INC 10/1/2006 10892 LUNSCO INC 1/1/1991 Y D 17205 LAYTON BIOSCIENCE, INC 1/1/2001 6/30/2010 10914 BRIGHTON PHARMACEUTICALS, IN 1/1/2006 17314 ALZA CORPORATION 1/1/1991 Y 10922 INTENDIS, INC 10/1/2005 17433 ENEMEEZ INC 4/1/2007 Y 11042 ADVANCIS PHARMACEUTICAL 1/1/2006 Y 17478 AKORN INC 1/1/1991 Y 11098 AKORN MANUFACTURING 1/1/1996 Y 18011 ZERIS PHARMA, LLC.
Load more

Recommended publications
  • 2009: Turning the Corner
    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
    [Show full text]
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
    [Show full text]
  • 28 May 2009 Thomas E. Costa
    The Third International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Thomas E. Costa 2828 MayMay 20092009 This presentation represents my own personal opinion and is not the official position of Bristol-Myers Squibb PhRMA Code 2009 • Updated in response to concerns of healthcare stakeholders • Reaffirms that interactions between pharmaceutical company representatives and healthcare professionals (HCPs) should: ¾ Inform HCPs about the benefits and risks of our products ¾ Provide scientific and educational information ¾ Obtain feedback and advice about our products through consultation with medical experts • The PhRMA Code is the new industry standard PhRMA Code Signatory Companies • Abbott • Eli Lilly and Company • Amgen, Inc. • Merck & Company, Inc. • Amylin Pharmaceuticals, Inc. • Millennium Pharmaceuticals, Inc. • Astellas US LLC • Novartis Pharmaceuticals • AstraZeneca LP Corporation • Bayer HealthCare • Novo Nordisk Inc. Pharmaceuticals • Otsuka America, Inc. • Boehringer Ingleheim • Ovation Pharmaceuticals, Inc. Pharmaceuticals, Inc. • Pfizer, Inc. • Bristol-Myers Squibb Company • Purdue Pharma LP • Cephalon, Inc. • sanofi-aventis US • Covidien Ltd. • Schering-Plough Corporation • Daiichi Sankyo, Inc. • Sepracor, Inc. • Eisai, Inc. • Signa-Tau Pharmaceuticals, Inc. • EMD Serono • Solstice Neurosciences, Inc. • Endo Pharmaceuticals, Inc. • Solvay Pharmaceuticals, Inc. • Genzyme Corporation • Takeda Pharmaceuticals North • GlaxoSmithKline America, Inc. • Hoffmann-La Roche, Inc. • Wyeth • Johnson and Johnson
    [Show full text]
  • Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena
    S. HRG. 113–859 WHY ARE SOME GENERIC DRUGS SKYROCKETING IN PRICE? HEARING BEFORE THE SUBCOMMITTEE ON PRIMARY HEALTH AND AGING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED THIRTEENTH CONGRESS SECOND SESSION ON EXAMINING THE PRICING OF GENERIC DRUGS NOVEMBER 20, 2014 Printed for the use of the Committee on Health, Education, Labor, and Pensions ( Available via the World Wide Web: http://www.gpo.gov/fdsys/ U.S. GOVERNMENT PUBLISHING OFFICE 24–459 PDF WASHINGTON : 2017 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Nov 24 2008 13:32 May 19, 2017 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\DOCS\24459.TXT DENISE HELPN-003 with DISTILLER COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS TOM HARKIN, Iowa, Chairman BARBARA A. MIKULSKI, Maryland LAMAR ALEXANDER, Tennessee PATTY MURRAY, Washington MICHAEL B. ENZI, Wyoming BERNARD SANDERS (I), Vermont RICHARD BURR, North Carolina ROBERT P. CASEY, JR., Pennsylvania JOHNNY ISAKSON, Georgia KAY R. HAGAN, North Carolina RAND PAUL, Kentucky AL FRANKEN, Minnesota ORRIN G. HATCH, Utah MICHAEL F. BENNET, Colorado PAT ROBERTS, Kansas SHELDON WHITEHOUSE, Rhode Island LISA MURKOWSKI, Alaska TAMMY BALDWIN, Wisconsin MARK KIRK, Illinois CHRISTOPHER S. MURPHY, Connecticut TIM SCOTT, South Carolina ELIZABETH WARREN, Massachusetts DEREK MILLER, Staff Director LAUREN MCFERRAN, Deputy Staff Director and Chief Counsel DAVID P. CLEARY, Republican Staff Director SUBCOMMITTEE ON PRIMARY HEALTH AND AGING BERNARD SANDERS, Vermont, Chairman BARBARA A.
    [Show full text]
  • Beyond Borders Global Biotechnology Report 2010
    Beyond borders Global biotechnology report 2010 To our clients and friends As economies around the world begin to recover from the worst diminished means, key constituents in the biotechnology economic crisis since the Great Depression, it is clear that a “new ecosystem — investors, pharmaceutical companies, payors, normal” is emerging. Among other things, this is a world in which governments and biotech firms — need to do more with less. capital flows are far more constrained than during the easy money- Companies that are able to develop creative solutions to boost fueled decade that preceded the downturn. What impact has this efficiency will be best positioned to succeed in the new normal. capital-constrained environment had on biotechnology — a business Readers of Beyond borders will notice some structural changes that is based on an enormous hunger for capital coupled with an in this year’s report. In prior years, we organized the report by exceptionally long path to commercial payback? geography, with sections on the Americas, Europe and Asia-Pacific. We set out to answer that question in this year’s Beyond borders. This year, we have instead organized the report thematically. As usual, we analyze key indicators of the industry’s performance: The Global perspective section brings together our point of view financing activity, deal trends, financial results, pipeline strength on salient trends and implications as well as some perspectives and product approvals. While the overall results are robust, the gap from company leaders. This is followed by a Country profiles between the industry’s haves and its have-nots has widened.
    [Show full text]
  • Pharmaceutical Company Contact Information (PDF)
    Pharmaceutical Company Contact Information - Rebate Filing - as of June 2018 Labeler Name Invoice Contact Phone Extension 00002 LILLY USA, LLC LISA NORTON (317) 276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS (609) 897-4731 00004 GENENTECH CONTRACT ADMINISTRATION (650) 866-2666 00005 LEDERLE LABORATORIES DAN MAGUIRE (484) 563-5097 00006 MERCK & CO., INC. DOUG BICKFORD (215) 652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00008 WYETH LABORATORIES JENNIFER WOOTEN (901) 215-1883 00009 PHARMACIA AND UPJOHN COMPANY/PFIZER JENNIFER WOOTEN (901) 215-1883 00013 PHARMACIA AND UPJOHN COMPANY NICHOLAS CHRISTODOULOU (336) 291-1053 00014 G. D. SEARLE & CO. CINDY MCDONALD (847) 581-5726 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS (609) 897-4731 00016 PHARMACIA INC. BARBARA WINGET (908) 901-7254 00023 ALLERGAN INC SHOBHANA MINAWALA (714) 246-6205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS (212) 551-4198 00025 PHARMACIA CORPORATION NICHOLAS CHRISTODOULOU (336) 291-1053 00026 BAYER CORPORATION PHARMACEUTICAL DIV. LINDA WOLCHESKI (203) 812-6372 00028 NOVARTIS PHARMACEUTICALS (862) 778-8094 00029 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00031 A. H. ROBINS COMPANY DAN MAGUIRE (610) 902-3222 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847) 937-3979 00033 SYNTEX LABORATORIES, INC. JANICE BRENNAN (973) 562-3494 00034 THE PURDUE FREDERICK COMPANY JUNE STOWE (203) 899-8035 00037 CARTER-WALLACE, INC. JAY R BRENNAN (609) 655-6163 00038 ASTRAZENECA LP DAVID WRIGHT (302) 886-2268 7820 00039 AVENTIS PHARMACEUTICALS (908) 981-7461 00043 NOVARTIS CONSUMER HEALTH, INC. EDWARD D. COLLINS (973) 781-6191 00044 KNOLL LABORATORIES DEBRA DEYOUNG (847) 937-4372 00045 MCNEIL PHARMACEUTICAL (908) 218-6777 00046 AYERST LABORATORIES (901) 215-1473 00047 WARNER CHILCOTT LABORATORIES LISA KAROLCHYK (973) 442-3262 00048 KNOLL PHARMACEUTICAL COMPANY DEBRA DEYOUNG (847) 937-4372 00049 ROERIG NICHOLAS CHRISTODOULOU (336) 291-1053 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847) 937-3979 00052 ORGANON, USA, INC.
    [Show full text]
  • USCIS - H-1B Approved Petitioners Fis…
    5/4/2010 USCIS - H-1B Approved Petitioners Fis… H-1B Approved Petitioners Fiscal Year 2009 The file below is a list of petitioners who received an approval in fiscal year 2009 (October 1, 2008 through September 30, 2009) of Form I-129, Petition for a Nonimmigrant Worker, requesting initial H- 1B status for the beneficiary, regardless of when the petition was filed with USCIS. Please note that approximately 3,000 initial H- 1B petitions are not accounted for on this list due to missing petitioner tax ID numbers. Related Files H-1B Approved Petitioners FY 2009 (1KB CSV) Last updated:01/22/2010 AILA InfoNet Doc. No. 10042060. (Posted 04/20/10) uscis.gov/…/menuitem.5af9bb95919f3… 1/1 5/4/2010 http://www.uscis.gov/USCIS/Resource… NUMBER OF H-1B PETITIONS APPROVED BY USCIS IN FY 2009 FOR INITIAL BENEFICIARIES, EMPLOYER,INITIAL BENEFICIARIES WIPRO LIMITED,"1,964" MICROSOFT CORP,"1,318" INTEL CORP,723 IBM INDIA PRIVATE LIMITED,695 PATNI AMERICAS INC,609 LARSEN & TOUBRO INFOTECH LIMITED,602 ERNST & YOUNG LLP,481 INFOSYS TECHNOLOGIES LIMITED,440 UST GLOBAL INC,344 DELOITTE CONSULTING LLP,328 QUALCOMM INCORPORATED,320 CISCO SYSTEMS INC,308 ACCENTURE TECHNOLOGY SOLUTIONS,287 KPMG LLP,287 ORACLE USA INC,272 POLARIS SOFTWARE LAB INDIA LTD,254 RITE AID CORPORATION,240 GOLDMAN SACHS & CO,236 DELOITTE & TOUCHE LLP,235 COGNIZANT TECH SOLUTIONS US CORP,233 MPHASIS CORPORATION,229 SATYAM COMPUTER SERVICES LIMITED,219 BLOOMBERG,217 MOTOROLA INC,213 GOOGLE INC,211 BALTIMORE CITY PUBLIC SCH SYSTEM,187 UNIVERSITY OF MARYLAND,185 UNIV OF MICHIGAN,183 YAHOO INC,183
    [Show full text]
  • Statement of Chairman Joseph J. Simons, Commissioner Noah Joshua Phillips, and Commissioner Christine S
    UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION WASHINGTON, DC 20580 Statement of Chairman Joseph J. Simons, Commissioner Noah Joshua Phillips, and Commissioner Christine S. Wilson Concerning the Proposed Acquisition of Allergan plc by AbbVie Inc. May 5, 2020 AbbVie Inc. (“AbbVie”), the seventh largest pharmaceutical company in the world by revenue, proposes to acquire Allergan plc (“Allergan”), the twentieth largest.1 The parties’ portfolios are largely complementary, as AbbVie primarily develops and markets products in the immunology, oncology, and virology areas, while Allergan is focused on aesthetics and eye care. This transaction poses competitive concerns in three relevant markets: (1) drugs for the treatment of exocrine pancreatic insufficiency (“EPI”); (2) Interleukin-23 (“IL-23”) inhibitors for the treatment of moderate-to-severe Crohn’s disease; and (3) IL-23 inhibitors for the treatment of moderate-to-severe ulcerative colitis. In these areas, the parties are two of a limited number of firms with products on the market or in development. The Commission has voted 3-2 to issue a complaint and accept a settlement resolving every substantial threat to competition uncovered by FTC staff and supported by the evidence, after a thorough investigation lasting ten months and involving more than forty interviews and the review of more than 430,000 documents. The proposed order remedies the competitive concerns by requiring the merging parties to divest Allergan’s EPI drugs Zenpep and Viokace to Nestlé, S.A. (“Nestlé”) and to transfer Allergan’s assets related to the IL-23 inhibitor brazikumab back to AstraZeneca plc (“AstraZeneca”), the drug’s original developer, by terminating the AstraZeneca license to Allergan.
    [Show full text]
  • Office of Sponsored Rseearch Annual Report
    Appendix 1: Detail Awards by Sponsor Sponsor Name FY07 Award Federal National Institute of Heart, Lung, and Blood $48,571,652.00 National Cancer Institute $47,118,627.59 National Institute of Child Health and Human Development $36,021,503.00 National Institute of General Medicine Science $30,503,207.61 US Agency for International Development $28,518,210.00 National Institute of Allergy and Infectious Diseases $22,575,655.00 National Science Foundation - Research $21,973,962.00 US Department of Education $20,656,776.00 National Institute of Diabetes, Digestive and Kidney Diseases $20,467,967.52 National Center for Research Resources $17,703,399.00 National Institute of Mental Health-NIH $15,444,116.88 National Institute of Neurologic Disorders and Stroke $11,870,830.00 National Institute of Environmental Health Sciences $10,155,578.00 National Institute of Dental and Craniofacial Research $9,930,748.00 National Institute on Drug Abuse $6,597,641.39 National Institute on Alcohol Abuse and Alcoholism $6,322,584.08 National Institute of Arthritis Musculoskeletal Skin Disease $6,003,908.06 US Environmental Protection Agency - GRANTS $5,900,293.00 Centers for Disease Control $5,530,614.00 National Center for Chronic Disease Prev and Health Promo(CDC) $5,293,659.00 National Institute on Aging $4,160,868.00 National Center for Human Genome Research $4,112,635.00 US Department of Energy $3,777,324.00 US Army Medical Research $3,744,464.00 National Institute of Nursing Research $3,664,814.00 Bureau of Health Professions $3,612,953.91 Maternal and
    [Show full text]
  • Advanced Sterilization Products Alpharma Pharmaceuticals
    Manufacturers/Wholesalers Street City ST Zip Abbott Diabetes Care Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Abbott Nutrition Abbott Pharmaceutical Products Group Abbott Point of Care Abbott Spine Abbott Vascular Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Anna CA 92705 Advanced Neuromodulation Systems, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Agencourt Bioscience Corporation Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allergan American, LLC. Allergan Holdings, Inc, Allergan Puerto Rico Holdings, Inc. Allergan Sales Allergan Sales Puerto Rico, Inc. Allergan Specialty Therapeutics, Inc. Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Allscripts, LLC. 2401 Commerce Drive Libertyville IL 60048 Alpharma Pharmaceuticals, LLC 1 New England Ave Piscataway NJ 08854 American Medical System, Inc 10700 Bren Road West Minnetonka MN 55343 Ameridose, LLC. 50 Fountain Street Framingham MA 01702 Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA AMO Sales and Service, Inc. Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 AMS- AMS Innovation Center 3070 Orchard Drive San Jose CA 95134 AMS Sales Corporation 10700 Bren Road West Minnetonka MN 55343 Amylin Pharmaceutical, Inc. 9360 Towne Center Drive San Diego CA 92121 Anda Pharmaceuticals, Inc.
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]
  • View Annual Report
    Enzon Pharmaceuticals 2006 Annual Report TRANSFORMING TOMORROW Enzon Pharmaceuticals 2006 Annual Report Jeffrey H. Buchalter Chairman, President and Chief Executive Offi cer Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefi ts such as reduced dosing frequency and less toxicity. Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company’s revenue base. TRANSFORMING EXPECTATIONS DEAR SHAREHOLDERS: In 2006, we received approval to market Oncaspar In 2006, the new Enzon became a reality. We successfully as a fi rst-line treatment for newly diagnosed patients implemented a signifi cant number of critical initiatives as with ALL. We continue to see additional opportunity part of our plan to transform the Company — creating a beyond the pediatric setting and possibly beyond ALL new Enzon that is technology based, product driven and — with ongoing investigator-sponsored studies in adults oncology focused. with ALL and an Enzon-sponsored clinical study in solid tumors and lymphoma. In building the new Enzon we have also transformed the corporate culture with a renewed sense of energy and Although expanding the use of Oncaspar was a key urgency.
    [Show full text]